GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Fulcrum Therapeutics
Fulcrum Therapeutics is a biotech company developing drugs to treat rare genetic diseases. Its stock price is driven by news of clinical trials. The chart reflects investor confidence in the potential of its scientific platform to create breakthrough drugs.
Share prices of companies in the market segment - Specialized pharma
Fulcrum Therapeutics is a biopharmaceutical company developing small-molecule drugs for the treatment of genetically determined rare diseases by modulating gene expression. We classify it as a "Specialty Pharmaceuticals" company. The chart below shows the dynamics of this segment.
Broad Market Index - GURU.Markets
Fulcrum Therapeutics is a biotech company developing treatments for rare genetic diseases by regulating gene expression. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Fulcrum shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
FULC - Daily change in the company's share price Fulcrum Therapeutics
Daily fluctuations in Fulcrum Therapeutics, which specializes in genetically determined diseases, reflect the high risks of the biotech sector. Change_co is an immediate reaction to news about clinical trials. This indicator forms the basis for analysis of the advanced biotech sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Fulcrum Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with FULC, which focuses on treating rare genetic diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Fulcrum is a biopharmaceutical company developing drugs to treat genetic diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Fulcrum's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Fulcrum Therapeutics
Fulcrum Therapeutics' year-to-date performance is a story of drug development targeting the root causes of genetic diseases. Its 12-month market cap fluctuates based on clinical trial data from its drugs for sickle cell anemia and muscular dystrophy, where any progress brings hope to patients and investors.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Fulcrum Therapeutics, Inc. is a clinical-stage biotechnology company developing drugs to treat rare genetic diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Fulcrum Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Fulcrum Therapeutics
The value of Fulcrum, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its drugs for the treatment of rare genetic diseases, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Fulcrum Therapeutics is a clinical-stage biotech company focused on developing drugs for the treatment of genetically determined rare diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it's possible to assess how its unique approach to gene expression modulation influences investor perception of its platform.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of Fulcrum Therapeutics, a gene therapy company, are extremely volatile and weakly correlated with the market. Their performance is determined by news about the progress of clinical trials. The chart shows that monthly price movements reflect investor expectations for scientific breakthroughs, rather than a reaction to macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Fulcrum Therapeutics
Fulcrum Therapeutics is a biopharmaceutical company focused on treating genetically determined diseases. Its weekly stock price is a story of scientific research, where any news from a laboratory or clinic can trigger sharp price movements.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Fulcrum, like the entire rare disease biotech sector, is extremely volatile. Weekly stock price movements in this segment often reflect broader scientific breakthroughs that influence investor interest in the entire sector. The chart illustrates this sectoral relationship.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Fulcrum Therapeutics is another biotech company whose stock exists in its own universe, reacting to clinical trial data. The chart clearly demonstrates how its weekly performance is isolated from general market fluctuations, following its own unique scientific trajectory.
Market capitalization of the company, segment and market as a whole
FULC - Market capitalization of the company Fulcrum Therapeutics
Fulcrum Therapeutics' market cap is a bet on treating the genetic causes of rare diseases. This biotech company's stock price reflects investors' faith in its approach to regulating gene expression. Its performance is a response to clinical trial data in hematology and neurology.
FULC - Share of the company's market capitalization Fulcrum Therapeutics within the market segment - Specialized pharma
Fulcrum Therapeutics is a biopharmaceutical company whose market share is based on its platform for regulating gene expression to treat rare genetic diseases. Its market capitalization reflects the potential of its breakthrough approach.
Market capitalization of the market segment - Specialized pharma
Fulcrum Therapeutics targets rare genetic diseases. How big is this industry? The chart below shows the overall market capitalization of the specialized pharmaceutical sector. Its growth reflects scientific progress and how companies are discovering huge opportunities to help patients with previously incurable diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Fulcrum Therapeutics chart is a bet on a new understanding of genetics. The company's market cap, which develops drugs that regulate gene expression, reflects its belief in its breakthrough platform for treating rare diseases. This diagram illustrates how fundamental science can lead to the development of new drugs.
Book value capitalization of the company, segment and market as a whole
FULC - Book value capitalization of the company Fulcrum Therapeutics
Fulcrum Therapeutics, a company focused on treating genetic diseases, owes its book value to its tangible assets: cutting-edge laboratories, scientific equipment, and significant financial reserves for clinical trials. The chart below shows how the company built its physical foundation for scientific breakthroughs.
FULC - Share of the company's book capitalization Fulcrum Therapeutics within the market segment - Specialized pharma
Fulcrum Therapeutics is a company focused on the genetic causes of disease. Its tangible assets include cutting-edge laboratories equipped for the screening and development of small molecules. These R&D centers are its physical platform for innovation. The chart shows the share of this specialized scientific infrastructure the company controls.
Market segment balance sheet capitalization - Specialized pharma
Fulcrum Therapeutics is a biotechnology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Fulcrum focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Fulcrum Therapeutics' assets include laboratories and R&D centers where it develops drugs to treat genetically determined diseases. The chart shows how the company built its scientific and material foundation for its clinical programs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Fulcrum Therapeutics
Fulcrum Therapeutics is a biotech company. Its market valuation reflects pure faith in its scientific platform for treating genetic diseases. The chart visualizes investors' hopes for a scientific breakthrough.
Market to book capitalization ratio in a market segment - Specialized pharma
Fulcrum Therapeutics is a biotech company specializing in the treatment of genetically determined rare diseases. Its valuation is based on the potential of its scientific platform. The chart shows a high premium to its stock, reflecting hopes for breakthrough treatments.
Market to book capitalization ratio for the market as a whole
Fulcrum Therapeutics is a biopharmaceutical company developing treatments for rare genetic diseases. Its current valuation, compared to the average, is a pure bet on the success of its scientific platform. Investors assess its potential to develop drugs for diseases for which there is currently no cure, which is unrelated to its tangible assets.
Debts of the company, segment and market as a whole
FULC - Company debts Fulcrum Therapeutics
Fulcrum Therapeutics, a biopharmaceutical company, develops drugs to treat genetically determined diseases. This chart shows its financial position. The company has no stable revenue and funds its expensive clinical trials with funds raised from investors, betting on the success of its scientific platform.
Market segment debts - Specialized pharma
Fulcrum Therapeutics is a clinical-stage biotech developing drugs for genetically determined rare diseases. Its debt load reflects its need for capital to fund expensive clinical trials. This chart shows how the company raises funds to advance its drug candidates through the complex stages of development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Fulcrum Therapeutics
Fulcrum Therapeutics is a biotech company working on treatments for genetically determined diseases. Its success is entirely dependent on the results of scientific research. This chart shows the company's reliance on debt to finance its expensive R&D. It reflects its financial vulnerability and dependence on external capital before approval.
Market segment debt to market segment book capitalization - Specialized pharma
Fulcrum Therapeutics is a biopharmaceutical company developing drugs to treat genetically determined rare diseases. This chart shows the debt burden in the biotech sector. It is a key indicator of the company's ability to fund its complex and expensive research in this cutting-edge field of medicine.
Debt to book value of all companies in the market
Fulcrum Therapeutics is a biotech company working on the treatment of genetically determined diseases. Its success depends entirely on the results of scientific research. This graph of total market debt is an indicator of the investment climate, which directly impacts the company's ability to finance its long-term and expensive developments.
P/E of the company, segment and market as a whole
P/E - Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company developing drugs to treat genetically determined rare diseases by modulating gene expression. This chart reflects investor confidence in the company's cutting-edge scientific platform. Its performance is speculative and depends on clinical trial success.
P/E of the market segment - Specialized pharma
Fulcrum Therapeutics is a biotech company developing drugs that target the underlying causes of rare genetic diseases by modulating gene expression. This is at the forefront of medical science. This chart shows the average valuation for the specialty pharmaceuticals sector, reflecting investor expectations for a breakthrough in the treatment of genetically determined diseases.
P/E of the market as a whole
Fulcrum Therapeutics is a biotech company developing drugs to treat rare genetic diseases. Its valuation is a pure bet on the success of its research and development. It has no connection to the general economic cycles depicted by this chart. Fulcrum's value is determined solely by the success or failure of its research.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Fulcrum Therapeutics
Fulcrum Therapeutics is a biopharmaceutical company developing small-molecule therapeutics for the treatment of genetically determined diseases by modulating gene expression. This chart reflects expectations for its innovative scientific platform. The company's valuation is a bet on the success of its clinical programs in rare diseases.
%20P%2FE%20Fulcrum%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Fulcrum-Therapeutics&v=1772679507262 "Chart of the company's future (projected) P/E Fulcrum Therapeutics")
Future (projected) P/E of the market segment - Specialized pharma
Fulcrum Therapeutics is a biotech company developing drugs to treat genetically determined rare diseases by modulating gene expression. This chart reflects investor confidence in its innovative scientific platform. Comparing forecasts with the sector reveals how highly the market values its chances of developing breakthrough drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772679507267 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Fulcrum Therapeutics is a biopharmaceutical company focused on genetically determined rare diseases. Its scientific approach is based on the regulation of gene expression. This overall risk appetite profile is critical to its ability to attract capital for expensive research in this cutting-edge but risky field of medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772679507280 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biotechnology company developing drugs for the treatment of genetically determined rare diseases. Its financial performance currently reflects R&D expenses. Future profitability is entirely dependent on the success of clinical trials and the commercialization of its innovative drugs.
Profit of companies in the market segment - Specialized pharma
Fulcrum Therapeutics develops drugs to treat genetically determined rare diseases, targeting the root causes of the conditions through the regulation of gene expression. This is at the forefront of biotechnology. The profitability chart for its sector demonstrates how breakthroughs in genetics are opening new markets and the high cost of success (or failure) in this innovative field.
Overall market profit
Fulcrum Therapeutics is a biopharmaceutical company developing drugs to treat rare genetic diseases by modulating gene expression. This is at the cutting edge of science. The company's potential success could not only change the lives of patients but also prove the effectiveness of a new therapeutic platform, opening the way to treatments for a variety of other diseases.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Fulcrum Therapeutics
Fulcrum Therapeutics develops drugs to treat rare genetic diseases by modulating gene expression. This chart shows the speculative expectations for its innovative scientific platform. Future profitability is entirely dependent on the success of clinical trials.
%20profit%20of%20the%20company%20Fulcrum%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Fulcrum-Therapeutics&v=1772679507316 "Graph of future (projected) profit of the company Fulcrum Therapeutics")
Future (predicted) profit of companies in the market segment - Specialized pharma
Fulcrum Therapeutics is a biopharmaceutical company focused on treating genetically determined diseases by regulating gene expression. The forecast chart reflects revenue expectations for the biotech industry, allowing one to assess the potential of the company's cutting-edge scientific approach to lead to breakthrough treatments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772679507322 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
The dynamics on this chart reflect expectations for a clinical-stage biotech company. Fulcrum Therapeutics' profit forecast depends on the success of its developments in treating genetically determined diseases. The trajectory reflects investor confidence in its scientific platform and the potential of future drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772679507325 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Fulcrum Therapeutics
Fulcrum Therapeutics develops drugs to treat genetically determined rare diseases. The company has no stable revenue. This chart shows its valuation based on the potential of its scientific platform. It is a bet that its approach to gene regulation will lead to the creation of effective drugs.
P/S market segment - Specialized pharma
Fulcrum Therapeutics is a biotech company developing drugs to treat genetically determined rare diseases by modulating gene expression. Its valuation is based on the potential of its developments. This chart shows the average valuation in the biotech industry, reflecting investor expectations for Fulcrum's future revenue if its innovative platform is successful.
P/S of the market as a whole
Fulcrum Therapeutics is a biotech company developing drugs to treat genetically determined rare diseases. Its approach is based on regulating gene expression. This graph, which displays the average revenue estimate for Fulcrum, highlights that its value is based on the breakthrough potential of its scientific platform, not on current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Fulcrum Therapeutics
Fulcrum Therapeutics is a biotech company developing drugs to treat genetically determined diseases by targeting gene expression. This chart reflects investor expectations for its scientific platform. It shows the market's assessment of the likelihood of success in its clinical trials and the potential of its innovative approach.
%20P%2FS%20Fulcrum%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Fulcrum-Therapeutics&v=1772679507364 "The graph of the company's future (projected) P/S Fulcrum Therapeutics")
Future (projected) P/S of the market segment - Specialized pharma
Fulcrum Therapeutics is a biopharmaceutical company developing treatments for genetically determined rare diseases. This chart compares market expectations for its future revenue with other specialty pharmaceutical companies. This valuation reflects investor confidence in its scientific platform and the potential of its clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772679507380 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Fulcrum Therapeutics is a biotech company working on the treatment of genetically determined rare diseases. Its approach is based on regulating gene expression. Success in its developments could lead to the creation of fundamentally new treatments. This potential is part of the long-term expectations for biotech reflected in this graph.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772679507389 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Fulcrum Therapeutics
Fulcrum Therapeutics is a biopharmaceutical company developing drugs to treat genetically determined rare diseases. While in clinical trials, it may not have stable revenue. This chart shows revenue from future sales after drug approval or from partnerships.
Sales of companies in the market segment - Specialized pharma
Fulcrum Therapeutics is a biopharmaceutical company focused on treating genetically determined diseases by modulating gene expression. Its approach is aimed at addressing the underlying cause of the disease. This chart shows overall pharmaceutical sales, illustrating the company's cutting-edge scientific developments and commercial potential in the field of genetic medicine.
Overall market sales
Fulcrum Therapeutics is a biotechnology company developing drugs to treat genetically determined diseases by regulating gene expression. This overall economic climate impacts Fulcrum through its investment climate. Funding for breakthrough but long-term scientific research is highly dependent on investor confidence in the market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Fulcrum Therapeutics
Fulcrum Therapeutics is a biopharmaceutical company developing treatments for rare genetic diseases. Its approach is based on gene expression modulation. Future revenues are dependent on the success of clinical trials and regulatory approval. This chart reflects analysts' speculative expectations for its innovative scientific platform.
%20sales%20of%20the%20company%20Fulcrum%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Fulcrum-Therapeutics&v=1772679507420 "Schedule of future (projected) sales of the company Fulcrum Therapeutics")
Future (projected) sales of companies in the market segment - Specialized pharma
Fulcrum Therapeutics is a biotech company developing drugs to treat genetically determined rare diseases. This chart shows projected revenue for the entire biotech sector. While it reflects overall sentiment, for Fulcrum, progress in clinical trials of its innovative therapies is key.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772679507444 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Fulcrum Therapeutics is a biopharmaceutical company developing treatments for genetically determined diseases. Its value depends on the success of clinical trials. This graph, reflecting the overall state of the economy, influences the investment climate. During periods of growth, investors are more inclined to finance risky but socially significant developments in the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772679507456 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biotech focused on genetically determined diseases. This chart reflects its financial discipline. It demonstrates how the company manages its significant research expenses while striving to develop a drug that will deliver high profitability in the future.
Market segment marginality - Specialized pharma
Fulcrum Therapeutics is a biotech company developing drugs to treat genetically determined rare diseases. It aims to address the root causes of these diseases. This chart depicts its operational structure during clinical trials, highlighting the high R&D expenditures typical of companies at the forefront of genetic medicine.
Market marginality as a whole
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company specializing in the treatment of genetically determined rare diseases. Its future profitability depends on the success of its innovative approach to modulating gene expression. This total market return chart highlights the high-risk, high-reward nature of biotechnology, where a single scientific breakthrough can change everything.
Employees in the company, segment and market as a whole
Number of employees in the company Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company developing drugs to treat genetically determined diseases by modulating gene expression. This graph shows the team's scientific staff. The growth is directly related to progress in clinical programs and the expansion of the research platform to new diseases.
Share of the company's employees Fulcrum Therapeutics within the market segment - Specialized pharma
This graph illustrates Fulcrum Therapeutics' cutting-edge approach. The company's pharmaceutical workforce is focused on developing drugs that regulate gene expression to treat rare genetic diseases, such as sickle cell anemia. This team of scientists strives to address the underlying causes of disease at the genetic level.
Number of employees in the market segment - Specialized pharma
Fulcrum Therapeutics is a biopharmaceutical company developing treatments for genetically determined rare diseases. Its approach is based on the modulation of gene expression. This graph illustrates how cutting-edge scientific concepts, such as epigenetics, are becoming the basis for new therapies and creating jobs for researchers at the forefront of science.
Number of employees in the market as a whole
Fulcrum Therapeutics, Inc. is a biotechnology company focused on genetically determined rare diseases. Its value is created in the laboratory. This general employment schedule is unrelated to its activities, which are focused on developing breakthrough treatments based on a deep understanding of genetics.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics develops drugs that regulate gene expression to treat genetic diseases. This chart demonstrates its scientific potential. The astronomical market capitalization per scientist reflects investors' faith in the company's breakthrough platform, which has the potential to create a whole new class of drugs.
%20of%20the%20company%20Fulcrum%20Therapeutics%20(FULC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Fulcrum-Therapeutics-FULC&v=1772679507499 "Chart of market capitalization per employee (in thousands of dollars) of the company Fulcrum Therapeutics (FULC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Fulcrum Therapeutics is a biotech company specializing in the treatment of genetically determined diseases. Its market capitalization per employee reflects the market's faith in its scientific platform. The chart shows the premium investors are willing to pay for a potential breakthrough in the treatment of rare diseases.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772679507499 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Fulcrum Therapeutics is a biotech company developing drugs to treat genetically determined rare diseases. This chart shows a high valuation per employee, which is typical for this sector. The company's value lies in its scientific platform and potential to create treatments for previously incurable diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772679507500 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics is a clinical-stage biotech company specializing in genetically determined rare diseases (e.g., sickle cell anemia). The company is not profitable. This chart shows the net loss (R&D costs) per scientist working on future drugs.
%20Chart%20Fulcrum%20Therapeutics%20(FULC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Fulcrum-Therapeutics-FULC&v=1772679507503 "Company Profit Per Employee (in thousands of dollars) Chart Fulcrum Therapeutics (FULC)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Fulcrum Therapeutics is a biotech company developing drugs to treat genetically determined rare diseases. It focuses on regulating gene expression. This graph shows the loss per employee during the R&D phase. It serves as a benchmark for assessing how intensively the company invests in its scientists to advance its innovative, yet risky, programs.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772679507518 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Fulcrum Therapeutics (FULC) is a clinical-stage biotech developing drugs to treat rare genetic diseases (such as muscular dystrophy). This graph shows the loss per employee. It reflects the high cost of R&D: each scientist and physician involved in research requires a huge investment that has not yet generated revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772679507519 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics is a biotech company developing drugs to treat genetically determined diseases. This chart reflects the company's clinical-stage activity. Revenue per employee is minimal and depends on partnerships rather than sales.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Fulcrum-Therapeutics-FULC&v=1772679507521 "Sales chart per company employee Fulcrum Therapeutics (FULC)")
Sales per employee in the market segment - Specialized pharma
Fulcrum Therapeutics is a biotech company developing drugs to treat genetically determined diseases by manipulating gene expression. This chart shows the average revenue per employee in the segment. For a clinical-stage company, this is a benchmark for productivity in the sector.
Sales per employee for the market as a whole
Fulcrum Therapeutics is a clinical-stage biotech company specializing in genetically determined rare diseases. They have no commercial products. This figure would be zero, as their scientific team is entirely focused on R&D and clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics is a biotech company developing drugs to treat rare genetic diseases. The bearish sentiment seen in this chart reflects the risks of R&D. Bears are betting that clinical trials will fail (for example, due to safety issues), a common occurrence in this sector.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Fulcrum-Therapeutics-FULC&v=1772679507584 "Short Shares Chart for the Company Fulcrum Therapeutics (FULC)")
Shares shorted by market segment - Specialized pharma
Fulcrum Therapeutics is a clinical-stage biotech company developing drugs to treat genetically determined blood disorders (such as sickle cell anemia). This chart reflects the overall sentiment in the sector, reflecting the high level of investor skepticism toward companies operating in this complex and competitive field.
Shares shorted by the overall market
Fulcrum Therapeutics (FULC) is a clinical-stage biotech company working on genetic diseases. It's a classic speculative story. This chart reflects investors' risk appetite. A rise in this indicator indicates risk aversion, which deprives companies like FULC of funding and sends their stock prices plummeting.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics is a biotech company focused on genetically determined diseases (such as sickle cell anemia). This is a bet on their R&D platform. This chart measures the extremes of speculative sentiment. It shows when the stock is "overbought" on positive data or "oversold" on negative news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Fulcrum-Therapeutics-FULC&v=1772679507600 "RSI 14 indicator chart for the company's stock Fulcrum Therapeutics (FULC)")
RSI 14 Market Segment - Specialized pharma
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on treating genetically determined diseases. They use their "gene regulation" approach to treat muscular dystrophies and sickle cell anemia. This chart reflects the overall sentiment in the biotech sector, helping to gauge how the market views this speculative industry.
RSI 14 for the overall market
Fulcrum Therapeutics (FULC) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast FULC (Fulcrum Therapeutics)
Fulcrum Therapeutics (FULC) is a biotech company developing drugs to treat rare genetic diseases by manipulating gene expression. This chart shows the average target price. It reflects analysts' speculative assessment of the likelihood of success in the company's clinical trials, particularly in the area of muscular dystrophy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-FULC-Fulcrum-Therapeutics&v=1772679507606 "A chart showing analyst consensus forecasts for the expected stock price. FULC (Fulcrum Therapeutics)")
The difference between the consensus estimate and the actual stock price FULC (Fulcrum Therapeutics)
Fulcrum is a biotech company focused on rare genetic diseases. Its FulcrumSeek platform searches for drugs that regulate gene expression. This is an R&D bet. This chart shows the difference between the consensus forecast and the price. It reflects analysts' confidence in this cutting-edge science and its R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-FULC-Fulcrum-Therapeutics&v=1772679507607 "A chart showing the difference between the consensus forecast and the actual stock price. FULC (Fulcrum Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Fulcrum Therapeutics is a biotech company developing drugs to treat rare genetic diseases (such as muscular dystrophy) by targeting gene regulation. This chart shows analysts' overall expectations for the specialty pharmaceuticals sector, reflecting their confidence in the success of this complex R&D platform.
Analysts' consensus forecast for the overall market share price
Fulcrum Therapeutics is a biotech company working on rare genetic diseases (such as muscular dystrophy). Their goal is to "switch on" genes that can compensate for the disease. This chart shows overall market sentiment. For Fulcrum, as for any biotech, how risk appetite (sentiment) influences their valuation is important. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Fulcrum Therapeutics
Fulcrum is a biotech company working at the forefront of genetics. Their platform (FulcrumSeek) explores ways to incorporate genes to treat rare diseases (such as sickle cell anemia). This chart represents pure R&D spend. It likely reflects market confidence in their scientific platform and early clinical data, rather than revenue.
AKIMA Market Segment Index - Specialized pharma
Fulcrum (FULC) is a clinical-stage biotech focused on rare genetic diseases; the company develops drugs (Losmapimod) that target the underlying causes of diseases (e.g., muscular dystrophy (FSHD)). This summary metric evaluates R&D. The chart shows the segment average. This benchmark: how does Fulcrum's R&D focus (on rare diseases) differentiate it from the average pharma company?
The AKIM Index for the overall market
Fulcrum Therapeutics is a biotech company focused on treating genetically determined rare diseases (muscular dystrophy). This chart, reflecting the market average, is an indicator of risk appetite. It shows the macro backdrop, which is critical for funding such speculative clinical-stage scientific projects.
